185 related articles for article (PubMed ID: 23901256)
1. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD).
Otsuji T; Nagai Y; Sho K; Tsumura A; Koike N; Tsuda M; Nishimura T; Takahashi K
Clin Ophthalmol; 2013; 7():1487-90. PubMed ID: 23901256
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.
Matsumiya W; Honda S; Kusuhara S; Tsukahara Y; Negi A
BMC Ophthalmol; 2013 Apr; 13():10. PubMed ID: 23557322
[TBL] [Abstract][Full Text] [Related]
3. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.
Shi X; Wei W; Zhang C
Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
[TBL] [Abstract][Full Text] [Related]
6. Foveal structure during the induction phase of anti-vascular endothelial growth factor therapy for occult choroidal neovascularization in age-related macular degeneration.
Kano M; Sekiryu T; Sugano Y; Oguchi Y; Ojima A; Itagaki K; Saito M
Clin Ophthalmol; 2015; 9():2049-56. PubMed ID: 26604674
[TBL] [Abstract][Full Text] [Related]
7. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
[TBL] [Abstract][Full Text] [Related]
8. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
[TBL] [Abstract][Full Text] [Related]
9. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Yoshida Y; Kohno T; Yamamoto M; Yoneda T; Iwami H; Shiraki K
Jpn J Ophthalmol; 2013 May; 57(3):283-93. PubMed ID: 23413039
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
[TBL] [Abstract][Full Text] [Related]
11. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Bessho H; Kusuhara S; Tsukahara Y; Negi A
J Ophthalmol; 2011; 2011():742020. PubMed ID: 21772985
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic study in age-related macular degeneration assessed with swept-source optical coherence tomography.
Teper SJ; Nowinska A; Pilat J; Wylegala E
Photodiagnosis Photodyn Ther; 2016 Mar; 13():108-113. PubMed ID: 26780119
[TBL] [Abstract][Full Text] [Related]
13. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
15. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size.
Nishimura Y; Taguchi M; Nagai T; Fujihara M; Honda S; Uenishi M
Clin Ophthalmol; 2012; 6():365-8. PubMed ID: 22419857
[TBL] [Abstract][Full Text] [Related]
17. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
[TBL] [Abstract][Full Text] [Related]
18. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
[TBL] [Abstract][Full Text] [Related]
19. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Rofagha S; Bhisitkul RB; Boyer DS; Sadda SR; Zhang K;
Ophthalmology; 2013 Nov; 120(11):2292-9. PubMed ID: 23642856
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy for polypoidal choroidal vasculopathy.
Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH
Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
